Table: Santen Pharm -9-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

06/02/2025 06:00

Feb 6 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2024        Dec 31, 2023     Mar 31, 2025 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              222.77              222.83           302.00    
                   (+0.0 pct)          (+11.5 pct)      (+0.0 pct)  
  Operating           35.20               36.16            44.50    
                   (-2.7 pct)                           (+15.5 pct) 
  Pretax              35.31               33.56            45.00    
                   (+5.2 pct)                           (+50.6 pct) 
  Net                 27.47               26.61            32.50    
                   (+3.2 pct)                           (+22.0 pct) 
  EPS Basic         78.21 yen           72.26 yen        92.22 yen  
  EPS Diluted       77.98 yen           72.05 yen                   
  Ann Div                               33.00 yen        36.00 yen  
  -Q2 Div           17.00 yen           16.00 yen                   
  -Q4 Div                               17.00 yen        19.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T